MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

37.46 2.24

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

36.53

Max

Põhinäitajad
By Trading Economics
Sissetulek	11M 51M
Müük	39M 239M
P/E Sektori keskmine	11.593 87.826
Aktsiakasum	1.08
Kasumimarginaal	21.242
Töötajad	268
EBITDA	14M 73M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+18.64% upside

Turustatistika
By TradingEconomics
Turukapital	429M 2.1B
Eelmine avamishind	35.22
Eelmine sulgemishind	37.46

Uudiste sentiment

By Acuity

34%

66%

106 / 372 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. jaan 2026, 23:11 UTC

Tulu

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7. jaan 2026, 22:55 UTC

Suurimad hinnamuutused turgudel

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7. jaan 2026, 21:39 UTC

Suurimad hinnamuutused turgudel

Raytheon Down Following Trump Post Criticizing Company

7. jaan 2026, 20:13 UTC

Suurimad hinnamuutused turgudel

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7. jaan 2026, 20:03 UTC

Suurimad hinnamuutused turgudel

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7. jaan 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. jaan 2026, 23:46 UTC

Market Talk

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7. jaan 2026, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7. jaan 2026, 23:34 UTC

Market Talk

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7. jaan 2026, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7. jaan 2026, 22:48 UTC

Market Talk

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7. jaan 2026, 22:46 UTC

Tulu

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7. jaan 2026, 22:45 UTC

Tulu

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Revolution Medicines Draws Takeover Interest -- 2nd Update

7. jaan 2026, 22:42 UTC

Tulu

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7. jaan 2026, 22:41 UTC

Tulu

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7. jaan 2026, 22:41 UTC

Tulu

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7. jaan 2026, 22:40 UTC

Suurimad hinnamuutused turgudel

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7. jaan 2026, 22:31 UTC

Market Talk

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7. jaan 2026, 22:22 UTC

Market Talk

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7. jaan 2026, 22:01 UTC

Market Talk

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. jaan 2026, 21:46 UTC

Market Talk

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7. jaan 2026, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7. jaan 2026, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7. jaan 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7. jaan 2026, 20:29 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Near Deal for Revolution Medicines -- Update

7. jaan 2026, 20:27 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7. jaan 2026, 19:58 UTC

Market Talk

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7. jaan 2026, 19:48 UTC

Suurimad hinnamuutused turgudel

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

18.64% tõus

12 kuu keskmine prognoos

Keskmine 43.6 USD 18.64%

Kõrge 55 USD

Madal 32 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

106 / 372 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.